Prosecution Insights
Prosecution Insights
24 pending office actions • 13 art units • 23 examiners • 0 of 24 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (29%) |
| §102 only | 2 (8%) |
| §112 only | 5 (21%) |
| Double-patenting only | 2 (8%) |
| No statute on record | 8 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 2 | 65.5% | +28.0% |
| GURLEY, JAMI MICHELLE | 1 | 50.0% | +19.3% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 72.3% | +30.2% |
| LI, BAO Q | 1 | 75.4% | +26.4% |
| WANG, RUIXUE | 1 | 56.2% | +25.7% |
| BOESEN, AGNIESZKA | 1 | 68.3% | +21.8% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 100.0% | +0.0% |
| SWITZER, JULIET CAROLINE | 1 | 42.0% | +54.0% |
| BUCKMASTER, MARLENE VRENI | 1 | 28.6% | +77.1% |
| FOLEY, SHANON A | 1 | 73.3% | +18.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552635 | DNA Encoded Nanoparticle Vaccine Against Human Papillomavirus, and Methods of Use Thereof | CORNELIUS, CLAIRE ADRIENNE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004964 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ROTAVIRUS | BUCKMASTER, MARLENE VRENI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 138d overdue |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | EDGINGTONGIORDANO, FRANCESCA | 37d overdue |
| 18251620 | DNA ENCODED NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | GILL, RACHEL B | 11d overdue |
| 18042796 | INTRADERMAL MERS-CoV VACCINE | GILL, RACHEL B | 12d |
| 18407958 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | LI, BAO Q | 40d |
| 18306548 | COMPOSITIONS AND METHODS FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES | SWITZER, JULIET CAROLINE | 83d |
| 18556414 | GLYCAN MODIFIED SPIKE RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | BOESEN, AGNIESZKA | 84d |
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | GURLEY, JAMI MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1671 | 6 |
| 1672 | 4 |
| 1643 | 2 |
| 1622 | 2 |
| 1682 | 1 |
| 1635 | 1 |
| 1615 | 1 |
| 1647 | 1 |
| 1646 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699081 | Novel Immune Cell Engagers For Immunotherapy | GURLEY, JAMI MICHELLE | — | — | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18588643 | MAGE-A VACCINES AND METHODS OF TREATMENT USING THE SAME | EDGINGTONGIORDANO, FRANCESCA | 1643 | Other | Non-Final OA | 37d overdue | Pending | Feb 27, 2024 |
| 18407958 | Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates | LI, BAO Q | 1671 | §103 | Non-Final OA | 40d | Pending | Jan 09, 2024 |
| 18566859 | SYNTHETIC DNA VACCINE IMMUNOGENIC IMPROVEMENTS | WANG, RUIXUE | 1672 | §103 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18556414 | GLYCAN MODIFIED SPIKE RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | BOESEN, AGNIESZKA | 1672 | DP | Non-Final OA | 84d | Pending | Oct 20, 2023 |
| 18552635 | DNA Encoded Nanoparticle Vaccine Against Human Papillomavirus, and Methods of Use Thereof | CORNELIUS, CLAIRE ADRIENNE | 1672 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18251620 | DNA ENCODED NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | GILL, RACHEL B | 1671 | Other | Non-Final OA | 11d overdue | Pending | May 03, 2023 |
| 18306548 | COMPOSITIONS AND METHODS FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES | SWITZER, JULIET CAROLINE | 1682 | Other | Final Rejection | 83d | Pending | Apr 25, 2023 |
| 18042796 | INTRADERMAL MERS-CoV VACCINE | GILL, RACHEL B | 1671 | §103 | Non-Final OA | 12d | Pending | Feb 24, 2023 |
| 18004964 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ROTAVIRUS | BUCKMASTER, MARLENE VRENI | 1672 | §103 | Final Rejection | — | Pending | Jan 10, 2023 |
| 18064482 | LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME | FOLEY, SHANON A | 1671 | Other | Non-Final OA | 138d overdue | Pending | Dec 12, 2022 |
| 18001116 | CORONAVIRUS DISEASE 2019 (COVID-19) COMBINATION VACCINE | STUART, CAREY ALEXANDER MC | 1671 | Other | Non-Final OA | 79d overdue | Pending | Dec 08, 2022 |
| 17995539 | REAWAKENING OF DORMANT TUMOR CELLS BY MODIFIED LIPIDS DERIVED FROM STRESS ACTIVATED NEUTROPHILS | KONOPKA, CATHERINE ANNE | 1635 | §103 | Non-Final OA | 182d overdue | Pending | Oct 05, 2022 |
| 17907697 | Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19 | ROSSI, JULIA ANNE LORRAIN | 1615 | — | Non-Final OA | 167d overdue | Pending | Sep 29, 2022 |
| 17905143 | TREATMENT OF CARM1-OVEREXPRESSING AND/OR ARID1A MUTANT CANCERS WITH IRE-1/XBP-1 INHIBITORS | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17759649 | CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY | BUNNER, BRIDGET E | 1647 | §102 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 17787729 | VACCINES AGAINST AFRICAN SWINE FEVER VIRUS, AND METHODS OF USING SAME | SIFFORD, JEFFREY MARK | 1671 | Other | Non-Final OA | — | Pending | Jun 21, 2022 |
| 17634968 | NOVEL LOX-1 ANTIBODY COMPOSITIONS, LOX1 NEUTRALIZATION ASSAY AND METHODS OF TREATMENT USING SAME | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | 162d overdue | Pending | Feb 12, 2022 |
| 17427434 | DNA-ENCODED BISPECIFIC T-CELL ENGAGERS TARGETING CANCER ANTIGENS AND METHODS OF USE IN CANCER THERAPUTICS | CUNNINGCHEN, KATHLEEN MARY | 1646 | DP | Final Rejection | — | Pending | Jul 30, 2021 |
| 16973603 | COMPOSITIONS AND METHODS FOR IN VIVO POST TRANSLATIONAL MODIFICATION | POPA, ILEANA | 1633 | §112 | Non-Final OA | 17d overdue | Pending | Dec 09, 2020 |
| 16943947 | Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer | FORD, VANESSA L | 1674 | §112 | Final Rejection | 6d | Pending | Jul 30, 2020 |
| 16347861 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST LYME DISEASE | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | 10d overdue | Pending | May 07, 2019 |
| 16098918 | DNA Monoclonal Antibodies Targeting IL-6 and CD126 | LEONARD, ARTHUR S | 1631 | §102 | Final Rejection | 31d overdue | Pending | Nov 05, 2018 |
| 18274514 | Compounds and Methods for Preventing, Treating, or Ameliorating Airway Disease | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial